University Medical Center Groningen
Groningen, Provincie Groningen, 9700, Netherlands
Location status: Recruiting
NCT Number: NCT07488104
Rationale: Of all individuals with diabetes, 19-34% develop a foot ulcer in their lifetime, and nearly 25% of these ulcers result in amputation. Ulcer prevention is often addressed by prescribing orthopedic shoes (OS). However, the effectiveness of OS is highly dependent on the individual shoe technician's skill and experience, and OS is frequently perceived as unattractive by users.
To overcome these limitations, the LEEF-shoe was developed. It eliminates the need for a fully individualized shoe technician approach by using a standardized protocol to determine the rocker settings. This may provide comparable plantar pressure relief, while potentially improving patient acceptance due to its more appealing design and simplified prescription process.
Objective: The primary objective is to determine whether the LEEF-shoe differs from standard-OS in terms of plantar pressure distribution. Secondary objectives are evaluation of wearing time and user acceptance of both footwear types.
Study design: This study is a randomized cross-over trial. Participants will complete pre- and post-tests for plantar pressure distribution, wearing time will be measured, and focus group sessions will assess user experience and acceptance.
Study population: A total of 30 adults (≥18 years old) with diabetes mellitus and peripheral neuropathy, at increased risk for foot ulceration, will be included.
Intervention:
All participants will receive two pairs of OS, a standard-OS and an additional OS (e.g., the LEEF-shoe), both provided through usual care channels. At handover, plantar pressure measurements will be performed. Participants will then wear each shoe model for four weeks, one after the other, with wearing time continuously monitored. Following the 8-week period, participants return for a standard control appointment with the OS-technician, during which post-test pressure measurements are taken. Subsequently, participants are allowed to wear either shoe based on personal preference for an additional four weeks, during which wearing time continues to be recorded. The study concludes with focus group sessions to explore experiences and acceptance.
Main study parameters/endpoints:
The primary outcome of the study is peak plantar pressure. It will be compared between the standard-OS and LEEF-shoe during the randomization visit. The secondary outcomes are peak plantar pressures in 7 foot regions, wearing time of the OS and user experience and acceptance, assessed through semi-structured focus groups.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participants will be screened for eligibility during their regular consultation with the prescribing physician and OS-technician. After inclusion, participants will follow standard care procedures, which include an initial shoe fitting, a midway fitting, the handover of both shoes, and two follow-up appointments. To minimize any potential risk associated with wearing the LEEF-shoe at home following the handover, it is required that the LEEF-shoe is at least equivalent to, or better than, the standard-OS in terms of function and safety. Since the LEEF-shoe is produced within the existing framework and standards of OS manufacturing, it is considered a variant of standard-OS and thus falls within the boundaries of standard care.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Groningen, Provincie Groningen, 9700, Netherlands
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The LEEF-shoe is a variant of a standard-OS and therefore follows identical classification. The LEEF-shoe is classified as custom-made medical devices under EU Medical Device Regulation (MDR), as they are prescribed in writing, designed with specific characteristics, and intended for the exclusive use of an individual patient. Consequently, they are exempt from CE-marking requirements. The processes at STEPP BV for these custom-made medical devices are ISO 13485 certified. This certification is also required for the production of medical devices. These processes are governed by Standard Operating Procedures (SOP), which describe how the process is to be carried out.
The LEEF-shoe utilizes a rocker algorithm (simple search) to optimize the shape. Both ways of producing OS (Standard-OS & LEEF-shoe) fit in the SOPs of STEPP BV, following ISO 13485.
Standard-OS shoes typically consist of a supplement onto which the outsole is attached. The upper encloses the supplement. The suppleme
The standard orthopaedic shoe, which is the care as usual solution in the Netherland. ISO 13485 certified and optimized individually.
Time frame: measured during the handover of both shoes, before the wearing periods.
Measured with the Pedar-X measurement system
Time frame: measured after the two wearing time periods (totalling 8 weeks)
Measured with the Pedar-X measurement system
Time frame: collected during the three subsequent wearing periods of four weeks
wearing time (adherence) measured with a orthotimer in each shoe
Time frame: measured during the handover of both shoes, before the wearing periods
The weight of both pair of orthopedic shoes.
Time frame: After enrollment, baseline
The weight of the participant.
Time frame: After completion of the total protocol, after 12 weaks of wearing the ortopedic shoes.
Semi-structured interview regarding acceptance.
Time frame: After enrollment, baseline
Height of the participant.
Time frame: After enrollment, baseline
the length of the feet of the participants.
Contact information is provided by the study sponsor or research team.
Jelmer Braaksma, PhD
CONTACT
Juha M Hijmans, PhD
CONTACT
University Medical Center Groningen
Other
Acronym: LEEF-shoe
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06753604
Arterial Occlusive Diseases, Arteriosclerosis
Izmir, Turkey (Türkiye)
View Trial DetailsNCT01474473
Cardiovascular Diseases, Diabetes Complications
Paris, France
View Trial DetailsNCT07712289
Diabetes, Diabetes Complications
Faisalābad, Punjab Province, Pakistan
View Trial DetailsNCT07436585
Diabetes, Diabetes Complications
Lahore, Pakistan
View Trial Details